Prudential Financial Inc. Has $8.70 Million Stock Holdings in Inari Medical, Inc. (NASDAQ:NARI)

Prudential Financial Inc. increased its holdings in shares of Inari Medical, Inc. (NASDAQ:NARI) by 9.2% during the 4th quarter, Holdings Channel.com reports. The fund owned 170,400 shares of the company’s stock after acquiring an additional 14,290 shares during the period. Prudential Financial Inc.’s holdings in Inari Medical were worth $8,699,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Smartleaf Asset Management LLC lifted its stake in Inari Medical by 128.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 634 shares of the company’s stock worth $33,000 after purchasing an additional 356 shares during the period. R Squared Ltd bought a new position in shares of Inari Medical during the 4th quarter worth approximately $45,000. GAMMA Investing LLC boosted its stake in Inari Medical by 66.8% in the 4th quarter. GAMMA Investing LLC now owns 1,963 shares of the company’s stock valued at $100,000 after buying an additional 786 shares in the last quarter. KBC Group NV boosted its stake in Inari Medical by 31.5% in the 4th quarter. KBC Group NV now owns 2,333 shares of the company’s stock valued at $119,000 after buying an additional 559 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its position in Inari Medical by 5.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,550 shares of the company’s stock valued at $130,000 after acquiring an additional 128 shares during the period. Institutional investors own 90.98% of the company’s stock.

Inari Medical Stock Performance

NASDAQ NARI opened at $79.97 on Friday. The stock has a market capitalization of $4.68 billion, a P/E ratio of -59.24 and a beta of 1.02. Inari Medical, Inc. has a 52 week low of $36.73 and a 52 week high of $79.99. The stock has a fifty day moving average of $79.87 and a 200-day moving average of $61.44.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. William Blair reissued a “market perform” rating on shares of Inari Medical in a report on Tuesday, January 7th. Wells Fargo & Company restated an “equal weight” rating and issued a $80.00 price target (up from $65.00) on shares of Inari Medical in a research report on Tuesday, January 7th. Canaccord Genuity Group reaffirmed a “hold” rating and set a $80.00 price objective (up from $74.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Truist Financial lifted their target price on shares of Inari Medical from $50.00 to $63.00 and gave the company a “hold” rating in a research note on Wednesday, December 18th. Finally, Baird R W lowered Inari Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 7th. Twelve research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, Inari Medical has an average rating of “Hold” and an average price target of $68.00.

Insider Activity at Inari Medical

In other Inari Medical news, Director William Hoffman sold 200,000 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $60.47, for a total transaction of $12,094,000.00. Following the completion of the sale, the director now directly owns 238,987 shares of the company’s stock, valued at approximately $14,451,543.89. The trade was a 45.56 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 10.60% of the stock is owned by company insiders.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.